Prostaglandin E 2 (PGE 2 ) stimulates the formation of osteoclastlike tartrate-resistant acid phosphatase-positive multinucleated cells (TRAP ϩ MNC) in vitro. This effect likely results from stimulation of adenylyl cyclase, which is mediated by two PGE 2 receptors, designated EP 2 and EP 4 . We used cells from mice in which the EP 2 receptor had been disrupted to test its role in the formation of TRAP ϩ MNC. EP 2 heterozygous (Ϯ) mice in a C57BL/6 x 129/SvEv background were bred to produce homozygous null (EP 2 Ϫ/Ϫ) and wild-type (EP 2 ϩ/ϩ) mice. PGE 2 , PTH, or 1,25 dihydroxyvitamin D increased TRAPϩ MNC in 7-day cultures of bone marrow cells from EP 2 ϩ/ϩ mice. In cultures from EP 2 Ϫ/Ϫ animals, responses to PGE 2 , PTH, and 1,25 dihydroxyvitamin D were reduced by 86%, 58%, and 50%, respectively. A selective EP 4 receptor antagonist (EP 4 RA) further inhibited TRAPϩ MNC formation in both EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ cultures. In cocultures of spleen and calvarial osteoblastic cells, the response to PGE 2 or PTH was reduced by 92% or 85% when both osteoblastic cells and spleen cells were from EP 2 Ϫ/Ϫ mice, by 88% or 68% when only osteoblastic cells were from EP 2 Ϫ/Ϫ mice and by 58% or 35% when only spleen cells were from EP 2 Ϫ/Ϫ mice. PGE 2 increased receptor activator of nuclear factor (NF)-kB ligand (RANKL) messenger RNA expression in osteoblastic and bone marrow cell cultures from EP 2 ϩ/ϩ mice 2-fold but had little effect on cells from EP 2 Ϫ/Ϫ mice. Spleen cells cultured with RANKL and macrophage colony stimulating factor produced TRAPϩ MNC. PGE 2 increased the number of TRAPϩ MNC in spleen cell cultures from EP 2 ϩ/ϩ mice but not in cultures from EP 2 Ϫ/Ϫ mice. EP 4 RA had no effect on the PGE 2 response in spleen cell cultures. PGE 2 decreased the expression of messenger RNA for granulocyte-macrophage colony stimulating factor in spleen cell cultures from EP 2 ϩ/ϩ mice but had little effect on cells from EP 2 Ϫ/Ϫ mice. These data demonstrate that the prostaglandin EP 2 receptor plays a role in the formation of osteoclast-like cells in vitro. A major defect in EP 2 Ϫ/Ϫ mice appears to be in the capacity of osteoblastic cells to stimulate osteoclast formation. In addition, there appears to be a defect in the response of cells of the osteoclastic lineage to PGE 2 in EP 2
osteoblastic cells were from EP 2 Ϫ/Ϫ mice and by 58% or 35% when only spleen cells were from EP 2 Ϫ/Ϫ mice. PGE 2 increased receptor activator of nuclear factor (NF)-kB ligand (RANKL) messenger RNA expression in osteoblastic and bone marrow cell cultures from EP 2 ϩ/ϩ mice 2-fold but had little effect on cells from EP 2 Ϫ/Ϫ mice. Spleen cells cultured with RANKL and macrophage colony stimulating factor produced TRAPϩ MNC. PGE 2 increased the number of TRAPϩ MNC in spleen cell cultures from EP 2 ϩ/ϩ mice but not in cultures from EP 2 Ϫ/Ϫ mice. EP 4 RA had no effect on the PGE 2 response in spleen cell cultures. PGE 2 decreased the expression of messenger RNA for granulocyte-macrophage colony stimulating factor in spleen cell cultures from EP 2 ϩ/ϩ mice but had little effect on cells from EP 2 Ϫ/Ϫ mice. These data demonstrate that the prostaglandin EP 2 receptor plays a role in the formation of osteoclast-like cells in vitro. A major defect in EP 2 Ϫ/Ϫ mice appears to be in the capacity of osteoblastic cells to stimulate osteoclast formation. In addition, there appears to be a defect in the response of cells of the osteoclastic lineage to PGE 2 P ROSTAGLANDINS are complex, multifunctional regulators of bone cell metabolism. A likely explanation for their multiple effects on bone cells is that different prostaglandin receptors mediate different actions (1) . Prostaglandin E 2 (PGE 2 ) is a major agonist in bone, and its predominant effects are to stimulate bone resorption and formation. These effects appear to be mediated by G protein-coupled receptors, which activate adenylyl cyclase. Four classes of receptors for PGE 2 have been identified, of which two, the EP 2 and EP 4 receptors, act by stimulating cAMP production (2) . Bone cells and marrow stromal cells can express both EP 2 and EP 4 receptors (3) (4) (5) . Attempts to analyze the relative importance of these two receptors by structure-activity studies are conflicting, perhaps, in part, because of the limited number and efficacy of selective agonists and antagonists for these receptors (6, 7) . The recent development of transgenic mice lacking functional EP 2 receptors (EP 2 Ϫ/Ϫ) has provided the opportunity to examine more precisely the role of this receptor in bone cell function (8) .
Osteoclast-like cell formation, as determined by tartrateresistant acid phosphatase-positive multinucleated cells (TRAP ϩ MNC) in bone marrow cultures and cocultures of spleen and osteoblastic cells, has been employed to study osteoclastogenesis since the 1980s (9 -11) . Receptor activator of nuclear factor (NF)-kB ligand (RANKL), also called TNFrelated activation induced cytokine (TRANCE), osteoclast differentiation factor (ODF) or osteoprotegerin ligand (OPGL) is clearly necessary for osteoclast formation (12, 13) . In addition, macrophage colony stimulating factor (M-CSF) is essential, but not sufficient, for osteoclast formation (14, 15) . A combination of RANKL and M-CSF stimulates osteoclast formation in spleen cell cultures (16) . There are also factors that can inhibit osteoclast formation. Osteoprotegerin (OPG) is a decoy receptor for RANKL, which blocks its interaction with RANK (17, 18) . Granulocyte/macrophage colony stimulating factor (GM-CSF) is also a potent inhibitor of osteoclast formation in the mouse system (19, 20) . PGE 2 stimulates osteoclast formation in bone marrow cultures (10, 21) , increases expression of messenger RNA for RANKL, and decreases OPG messenger RNA (mRNA) expression in osteoblastic cells (13, 22) . While these studies suggested that PGE 2 acts on osteoblastic cells to stimulate osteoclast formation, a recent study suggested that PGE 2 may also act synergistically with RANKL and M-CSF on hematopoietic precursors to induce TRAPϩ MNC (23) . PGE 2 inhibits GM-CSF production in bovine lymphocytes (24) .
In the present study, we compared the ability of EP 2 wildtype (EP 2 ϩ/ϩ) and knockout (EP 2 Ϫ/Ϫ) mice to form TRAP ϩ MNC in cultures of murine bone marrow, in cocultures of spleen cells and osteoblast-like cells, and in spleen cell cultures stimulated with PGE 2 in the presence of RANKL and M-CSF. RANKL and OPG mRNA expression in osteoblastic and bone marrow cell cultures and GM-CSF mRNA expression in spleen cell cultures were also examined. We found that cultures from EP 2 Ϫ/Ϫ mice showed a decreased osteoclastogenic response not only to PGE 2 but also to PTH and 1,25-dihydroxyvitamin D [1,25-(OH) 2 D 3 ]. The major defect appeared to be in the cells of osteoblastic lineage, which support osteoclast differentiation. There also appeared to be an additional defect in the response of the cells of hematopoietic lineage, which form osteoclasts.
Materials and Methods Animals
The prostaglandin EP 2 receptor gene was disrupted by replacing part of the N-terminal coding sequence with a PGK-neo cassette. Embryonic stem cell clones were obtained from transfected 129/SvEvTac-derived TL1 cells, and chimeric mice were derived from these cells crossed with C57BL/6 mice (8). The resulting EP 2 heterozygous (ϩ/Ϫ) F1 animals in a C57BL/6 X 129/SvEv background were bred to produce homozygous (Ϫ/Ϫ) null mice, heterozygous (ϩ/Ϫ), and wild-type (ϩ/ϩ) mice. Animals were housed in the Center for Laboratory Animal Care at the University of Connecticut Health Center. All animal protocols were approved by the Animal Care Committee of University of Connecticut Health Center.
Materials
Alpha MEM (␣-MEM) and FCS were purchased from Life Technologies, Inc. (Grand Island, NY). PGE 2 
Genotyping of mice
When the mice were 3-4 weeks old, ears were punched or notched for identification. Tail samples were obtained for analysis by PCR. Primer sequences were as follow: mEP 2 .249s: 5Ј-ccg ggg ttc tgg gga atc-3Ј; pPNT.1803s: 5Ј-ttg cca agt tct aat tcc atc aga-3Ј; and mEP 2 .801a: 5Ј-cat gcg aat gag gtt gag gat aa-3Ј. mEP 2 .249s and pPNT.1803s amplify the wild-type gene and give a 575-bp single band; pPNT.1803s and mEP 2 .801a amplify the recombinant gene and give a 295 bp single band. The conditions for PCR of the EP 2 receptor were 1 cycle for 1 min at 95 C; 35 cycles for 30 s at 95 C, 30 s at 56 C, and 1 min at 72 C. Products were electrophoresed on a 2% agarose gel in 1 ϫ TAE buffer at 100 V. Positive controls for each genotype were included in each amplification, as was a negative control (no DNA).
Bone marrow cell cultures
Mouse bone marrow cells were isolated by a modification of previously published methods (9, 10) . Most experiments were done when the mice were 5-6 weeks old. However, in some experiments the mice were 3-4 months old. Bone ends of aseptically dissected tibiae were cut off with scissors, and the marrow cavities were flushed with 1 ml ␣-MEM. The collected marrow cells were washed twice with ␣-MEM and cultured in 0.5 ml of ␣-MEM containing 10% FCS at 1 ϫ 10 6 cells/well in 24-well plates (Costar, Corning, NY). The cultures were fed every 3 days by replacing 0.4 ml of old medium with fresh medium. Osteoclast-like cell formation, which was determined as TRAP ϩ MNC formation, was evaluated in the presence or absence of PGE 2 (1 m), 1, 25(OH) 2 D 3 (10 nm), PTH (10 nm), or EP 4 RA (1 m). All cultures were maintained at 37 C in a humidified atmosphere of 5% CO2 in air. After being cultured for 7 days, the cells were washed with PBS and fixed with 2.5% glutaraldehyde in PBS for 30 min at room temperature. TRAP staining was performed with a commercial kit (leukocyte acid phosphatase kit, Sigma). TRAP ϩ MNC per well were counted in six separate wells for each condition of culture.
Spleen and calvarial osteoblastic cell cocultures
Mouse osteoblastic cells were obtained by sequential collagenase digestion (26) . Briefly, calvariae from 5-week-old mice were dissected free of loosely adherent fibrous tissue. Calvariae were then washed in PBS and incubated at room temperature with gentle shaking for five sequential 20 min digestions, each with 4 ml of 0.1% bacterial collagenase (Collagenase P, Roche Molecular Biochemicals, Indianapolis, IN), 0.05% trypsin, and 4 mm Na2 EDTA in Ca 2ϩ , Mg 2ϩ free PBS. After each digestion, calvariae were placed in fresh digestion solution, and the liberated cells were collected by centrifugation and washed three times in 3 ml of ␣-MEM with 10% heat-inactivated FCS (Life Technologies, Inc.). Cell populations harvested from the second to the fifth digestions were combined and cultured to confluence in ␣-MEM with 10% FCS in 100-mm plates.
Spleens from 6-week-old EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ mice were processed to produce a suspension of spleen cells in ␣-MEM containing 10% FCS as previously described (16) . Spleen cells (1 ϫ 10 6 cells/well) were co-cultured with osteoblastic cells (1 ϫ 10 4 cells/well) in 0.5 ml ␣-MEM supplemented with 10% FCS in 24-well plates as described previously (11) . Cultures were maintained for 7 days following the same protocol described for bone marrow cultures. Osteoclast formation estimated by TRAP ϩ MNC formation in the coculture system was evaluated in the presence or absence of PGE 2 (1 m) and PTH (10 nm). At the end of the culture period, the cells were stained for TRAP and TRAP ϩ MNC per well were counted in six separate wells for each culture condition.
Spleen cell cultures
Spleens from EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice (6 weeks old) were processed as described above. Spleen cells (1 ϫ 10 6 cells/well) were cultured in 0.5 ml ␣-MEM supplemented with 10% FCS in 24-well plates both in the presence and absence of M-CSF (10 ng/ml) and RANKL (10 ng/ml). The RANKL and M-CSF-treated spleen cultures were further treated with or without PGE 2 (1 m) and a selective EP 4 RA (1 m). In all cultures, medium and added factors were replaced every 3 days. On day 7 of culture, the cells were stained and TRAPϩ MNC were counted. RANKL and M-CSF-treated spleen cultures were also treated with GM-CSF (1 ng/ml) with or without PGE 2 (1 m), a polyclonal antibody (1 g/ml) to GM-CSF (Anti-GM-CSF) or IgG (1 g/ml). TRAPϩ MNC formation was measured as above.
Pit formation assay
Bone resorption was assayed by measuring the ability of cultured bone marrow cells to form resorption pits on devitalized bovine cortical bone slices (4.4 ϫ 4.4 ϫ 0.2 mm) using previously described methods (27) . Briefly, trypsinized bone marrow cells that had been cultured for 7 days with or without PGE 2 were transferred onto the surface of bone slices for 90 min in PBS. Bone slices were rinsed vigorously and incubated for 24 h at 37 C in ␣-MEM (0.7 g of sodium bicarbonate per liter) with 10% HIFCS. After incubation, bone slices were stained with 1% toluidine blue in 1% borax. The number of resorption pits was counted using reflected light microscopy.
Northern blot analysis
The osteoblastic cells of EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice were obtained as described above. After 6-days of culture, the cells were treated with PGE 2 (1 m) or vehicle for 24 h and RNA was extracted by the acid guanidine isothiocyanate method (28, 29) . Bone marrow cells were cultured with PGE 2 (1 m) or vehicle for 7 days, and total RNA was extracted by the same method.
After quantitation at 260 nm, 20 g of RNA was run on a 1% agrose-2.2 m formaldehyde gel, transferred to a nylon membrane (GeneScreen plus; NEN Life Science Products, Boston, MA) by Turboblotter (Schleicher & Schuell, Keene, NH) and fixed to the membrane by UV irradiation (Stratolinker; Stratagene). After 3 h of prehybridization in 50% formamide solution at 42 C, filters were hybridized overnight at 42 C in a similar solution with random primer [
32 P] dCTP-labeled complementary DNA probe for RANKL, OPG or G3PDH. [ 32 P] dCTP was from NEN Life Science Products. Filters were washed once in a 1 ϫ SSC, 1% SDS solution at room temperature, once in a 0.1 ϫ SSC, 0.1% SDS solution at 65 C, and then three more times in the latter solution at room temperature. After washing, the filter was exposed to Kodak XAR-5 film at Ϫ70 C. Images were digitalized by scanner (ScanJet, Hewlett-Packard Co., Corvallis, OR) connected to a computer (Power Macintosh 7500/ 100), and optical density was determined using a digital image processing and analysis program (NIH Image 1.61, NIH, Bethesda, MD).
RNA extraction and reverse transcriptase PCR amplification for spleen cell cultures
Spleen cells (5 ϫ 10 6 cells/well) were plated and maintained in 2 ml ␣-MEM supplemented with 10% FCS in 6-well plates both in the absence and presence of M-CSF (10 ng/ml) and ODF (10 ng/ml). The RANKL and M-CSF-treated spleen cultures were further treated with or without PGE 2 (1 m). RNA was extracted after a 7-day treatment. RT and PCR were done as previously reported (29, 30) . Briefly, 2 g aliquots of total RNA were reverse-transcribed using oligo (dT) as a primer (1.5 m final concentration) in 30 l of RT-solution. Five microliters of RT-solution were then amplified.
EP 2 receptor PCR. Primer sequences for EP 2 receptor were as follow: forward mEP 2 receptor: 5Ј-cca cca tgg act aca agg acg acg atg aca agg aca att ttc tta atg act c-3Ј; reverse mEP 2 receptor: 5Ј-agc gca tcc tca caa ctg tc-3Ј. The conditions for PCR of the EP 2 receptor were 30 cycles for 45 sec at 94 C, 45 sec at 57 C, and 2 min 15 sec at 72 C. Products were electrophoresed on a 1% agarose gel in 1 ϫ TBE buffer at 100 V, stained with ethidium bromide and photographed under UV illumination. Positive controls for each genotype were included in each amplification, as was a negative control (no DNA). Images were captured by Alpha Imager 2200 Documentation & Analysis System (Alpha Innotech Co., San Leandro, CA). Optical density was determined as described above.
G3PDH PCR.
Primer sequences for G3PDH were as follow: forward G3PDH: 5Ј-tga agg tcg gtg tga acg gat ttg gcc-3Ј; reverse G3PDH: 5Ј-cat gta ggc cat gag gtc cac cac-3Ј. The conditions for PCR of the G3PDH were 27 cycles for 45 sec at 94 C, 45 sec at 57 C, and 2 min 15 sec at 72 C. The amplified samples were run as described above. Images and optical density were processed as described above.
GM-CSF PCR. PCR amplification was done using gene-specific PCR primers and Taq polymerase (Life Technologies, Inc.). Specific amplifier sets for GM-CSF were purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). The amplification cycle consisted of denaturation at 94 C for 45 sec, annealing at 60 C for 45 sec, and extension at 72 C for 2 min for 35 cycles. After the last cycle, the mixture was incubated at 72 C for 7 min. The amplified samples were run as described above. Images and optical density were processed as described above.
Statistical analysis
The significance of the difference between two groups was evaluated with unpaired two-tailed Student's t test. The comparisons among multiple groups were done by one-way ANOVA with significance determined by Scheffé's method.
Results

Phenotype of EP 2 Ϫ/Ϫ mice
There was no significant difference in body weights between EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice at the age of 5-6 weeks. The mean body weights were 20.5 Ϯ 1.1 g (n ϭ 6) for male EP 2 ϩ/ϩ mice, 21.8 Ϯ 0.9 g (n ϭ 6) for male EP 2 Ϫ/Ϫ mice, 18.9 Ϯ 0.7 g (n ϭ 6) for female EP 2 ϩ/ϩ mice and 17.7 Ϯ 0.9 (n ϭ 6) for female EP 2 Ϫ/Ϫ mice, respectively. There was no observable difference in activity or appearance between EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice. There were no obvious defects in the spleen, thymus, blood, and bone marrow of the EP 2 Ϫ/Ϫ mice for T cells, B cells, macrophages, and neutrophils (Singh, N., and L. Van Kaer, Vanderbilt University, personal communication). Histologic studies of the humerus from three 4-month-old EP 2 Ϫ/Ϫ mice showed no gross abnormality of the growth plate or metaphyseal bone compared with EP 2 ϩ/ϩ mice (data not shown). 
Spleen and osteoblastic cell cocultures
Cocultures without stimulation. Unstimulated cultures produced few TRAP ϩ MNC and showed a significant (P Ͻ 0.05) decrease when either spleen cells or osteoblasts in the cocultures were from EP 2 Ϫ/Ϫ mice (Fig. 2) .
Treatment with PGE 2 . PGE 2 treatment increased TRAPϩ MNC after 7 days of culture when EP 2 ϩ/ϩ osteoblastic cells were cocultured with EP 2 ϩ/ϩ spleen cells (Fig. 2 , Table 2 ). PGE 2 -treated cocultures of EP 2 Ϫ/Ϫ osteoblastic cells and EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ spleen cells showed a marked decrease (88 -92%) in TRAPϩ MNC formation in three different experiments. There were also 43 to 64% fewer TRAPϩ MNC when EP 2 ϩ/ϩ osteoblastic cells were co-cultured with EP 2 Ϫ/Ϫ spleen cells in three different experiments (Fig. 2 , Table 2 ).
Treatment with PTH. PTH treatment increased TRAPϩ MNC formation after 7 days of culture when EP 2 ϩ/ϩ osteoblastic cells were co-cultured with EP 2 ϩ/ϩ spleen cells (Table 2) . PTH-treated cocultures of EP 2 Ϫ/Ϫ osteoblastic cells and EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ spleen cells showed a marked decrease (68 -85%) in TRAPϩ MNC formation in two different experiments. There were also 21-48% fewer TRAPϩ MNC when EP 2 ϩ/ϩ osteoblastic cells were cocultured with EP 2 Ϫ/Ϫ spleen cells in two different experiments.
Spleen cell cultures
Cultured spleen cells treated with RANKL plus M-CSF from EP 2 ϩ/ϩ mice expressed the EP 2 receptor (Fig. 3) and expression of EP 2 receptor mRNA decreased after 7 days of treatment with PGE 2 . No EP 2 receptor mRNA signal was obtained from EP 2 Ϫ/Ϫ cells.
Spleen cells that were cultured without RANKL and M-CSF did not form TRAP ϩ MNC. In contrast, spleen cells from EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ mice that were incubated for 7 days with 10 ng/ml RANKL and 10 ng/ml M-CSF, formed similar numbers of TRAPϩ MNC (Fig. 4) . PGE 2 (1 m) increased TRAPϩ MNC by 2.5 fold in RANKL and M-CSF-treated EP 2 ϩ/ϩ spleen cultures. However, PGE 2 had no effect on TRAP ϩ MNC formation in EP 2 Ϫ/Ϫ spleen cell cultures. Furthermore, EP 4 RA did not alter the number of TRAP ϩ MNC that formed in either EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ spleen cultures that were treated with RANKL and M-CSF. In another experiment, PGE 2 in the presence of RANKL and M-CSF increased TRAPϩ MNC 5-fold in EP 2 ϩ/ϩ spleen cultures, while it had no effect on the number of TRAPϩ MNC that formed in EP 2 Ϫ/Ϫ spleen cell cultures (data not shown).
Pit formation
To test whether the TRAP ϩ MNC formed in bone marrow cultures were true osteoclasts, cells were transferred to bovine bone slices to determine their ability to form resorption pits. As shown in Fig. 5 , PGE 2 -treated cultures of EP 2 ϩ/ϩ bone marrow cells produced numerous large pits (20.2 Ϯ 0.5/slice) compared with 0.5 Ϯ 0.3 pits/slice in control cultures. PGE 2 -treated EP 2 Ϫ/Ϫ cultures produced 2.0 Ϯ 0.6 pits/slice compared with 0.8 Ϯ 0.4 in control cultures. While fewer pits were produced by PGE 2 -treated EP 2 Ϫ/Ϫ cultures, the pits that did form were of similar appearance and size to those in cultures from EP 2 ϩ/ϩ mice.
mRNA expression of RANKL and OPG
Murine RANKL and OPG mRNA expression was measured by Northern blot analysis in osteoblastic cell cultures (Fig. 6A ) and bone marrow cell cultures (Fig. 6B ) from EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice. Control cultures of primary osteoblastic cells expressed RANKL and OPG mRNA. PGE 2 treatment increased relative RANKL mRNA expression by 117% in osteoblastic cell cultures of EP 2 ϩ/ϩ mice, but by only 34% in cultures of EP 2 Ϫ/Ϫ mice. There was little effect of PGE 2 on OPG mRNA expression in osteoblastic cell cultures. In bone marrow cultures, 7 days of PGE 2 treatment increased RANKL mRNA expression by 115% in EP 2 ϩ/ϩ cultures, whereas there was only a 30% increase in EP 2 Ϫ/Ϫ cultures, as in osteoblastic cells. PGE 2 had little effect on OPG mRNA expression in EP 2 ϩ/ϩ bone marrow cell cultures.
GM-CSF mRNA expression and effect of GM-CSF
Murine GM-CSF mRNA expression was measured by RT-PCR in spleen cell cultures. Spleen cells from EP 2 ϩ/ϩ and EP 2 Ϫ/Ϫ mice were treated with or without PGE 2 in the presence of M-CSF and RANKL for 7 days. PGE 2 decreased GM-CSF mRNA expression in spleen cell cultures from EP 2 ϩ/ϩ by 72% but by only 27% in cultures from EP 2 Ϫ/Ϫ mice (Fig. 7) . GM-CSF treatment inhibited TRAPϩ MNC formation in EP 2 ϩ/ϩ cultures and blocked the effect of PGE 2 (Fig.  8) . A neutralizing polyclonal antibody to murine GM-CSF increased TRAPϩ MNC in cultures treated with RANKL and M-CSF and reversed the inhibitory effects of GM-CSF (Fig.  8 ) but did not further increase the number of TRAPϩ MNC in PGE 2 -treated cultures (data not shown). Nonspecific IgG did not reverse the inhibitory effects of GM-CSF.
Discussion
The present study demonstrates that cells from mice lacking a specific prostaglandin E receptor, the EP 2 receptor, have a decreased ability to form osteoclast-like cells in both bone marrow cultures, and cocultures of spleen cells and calvarial osteoblastic cells. The MNC that formed in bone marrow cultures expressed tartrate-resistant acid phosphatase, were multinucleated, and formed resorption pits on bovine bone slices. Hence, they appear to have many characteristics of authentic osteoclasts. Formation of osteoclast-like cells in response to PGE 2 was markedly decreased in bone marrow cultures from EP 2 Ϫ/Ϫ mice. Cultures from EP 2 Ϫ/Ϫ mice also formed fewer osteoclast-like cells in response to PTH and 1,25(OH) 2 TRAPϩ MNC formation. However, we observed this increase only in EP 2 ϩ/ϩ cells, and not in EP 2 Ϫ/Ϫ spleen cells. Spleen cell cultures from EP 2 ϩ/ϩ mice expressed EP 2 receptor mRNA but the cell type is unknown. In addition, PGE 2 treatment of EP 2 ϩ/ϩ spleen cell cultures decreased EP 2 receptor mRNA expression, this could be due to a loss of cell types or down-regulation of receptor expression.
The defect in the ability of osteoblastic cells from EP 2 Ϫ/Ϫ mice to support osteoclastogenesis was demonstrated by an 88% decrease in osteoclast-like cell formation in PGE 2 -treated cultures and a 68% decreased in PTH-treated cultures when EP 2 ϩ/ϩ spleen cells were cultured with EP 2 Ϫ/Ϫ osteoblastic cells compared with cocultures of EP 2 ϩ/ϩ spleen cells with EP 2 ϩ/ϩ osteoblastic cells. The defect in EP 2 Ϫ/Ϫ osteoblast-like cells was associated with a decrease in the ability of PGE 2 to increase RANKL, whereas the defect in EP 2 Ϫ/Ϫ spleen cells was associated with a failure of PGE 2 to decrease GM-CSF mRNA expression. Increased RANKL and decreased OPG mRNA expression have been demonstrated in response to stimulators of bone resorption (31) . Changes in the balance between RANKL and OPG mRNA expression may be important in the role of PGs in regulating osteoclast formation. However, further studies of protein levels as well as exploration of other pathways are needed to confirm this hypothesis.
It is likely that the ability of PGE 2 to increase TRAP ϩ MNC number in spleen cell cultures treated with RANKL and M-CSF depends on the action of PGE 2 to inhibit GM-CSF production. GM-CSF has previously been shown to inhibit osteoclastogenesis in bone marrow cultures, and it is the mediator of the inhibitory effect of IL-18 on osteoclast like cell formation (20) . Moreover decreased GM-CSF production has previously been observed in bovine lymphocytes treated with PGE 2 (24) . In our culture system, GM-CSF blocked osteoclast-like cell formation. An antibody to GM-CSF reversed the effect of GM-CSF but did not further increase the response to PGE 2 . Recent experiments with cells from mice in which the inducible cyclooxygenase (COX-2) gene was knocked out confirm the effect of PGE 2 on GM-CSF production (Okada, Y., and C. C. Pilbeam, unpublished data). It is possible that endogenous prostaglandins, produced by COX-2, may increase osteoclast number by diverting cells that might otherwise differentiate along the macrophage pathway toward the osteoclast lineage.
Stimulation of adenylyl cyclase by prostaglandins can be mediated not only by the EP 2 , but also by the EP 4 receptor. Recent studies suggest that animals lacking a functional EP 4 receptor also have a defect in osteoclast-like cell formation in bone marrow cultures and co-cultures of spleen and calvarial osteoblastic cells (32, 33) . In our own studies, we have found that a recently developed EP 4 receptor selective inhibitor can further reduce the number of TRAPϩ MNC in marrow cultures from either EP 2 ϩ/ϩ or EP 2 Ϫ/Ϫ mice. However, a role for EP 4 has been demonstrated only in cells of the osteoblast lineage and not in the hematopoietic osteoclast precursors (32) . Our results confirm this finding because we showed that EP 4 RA reduced osteoclast formation in bone marrow cultures but had no effect on the stimulation of osteoclast-like cell formation by PGE 2 in spleen cell cultures that were treated with M-CSF and RANKL.
A role for prostaglandins in osteoclast production in response to other stimulators, including PTH, 1,25(OH) 2 D 3 , FGF-2 and IL-1, has been suggested by studies that use nonsteroidal antiinflammatory drugs to inhibit prostaglandin production (1, 27, 30, 34 -36) . Recent data from our laboratory indicate that endogenous prostaglandin production, which facilitates osteoclast-like cell formation, is dependent upon the presence of COX-2 (37) . In contrast to these cell culture experiments, studies using organ cultures or in vivo models to demonstrate a role for endogenous prostaglandins in the resorptive response to different stimulators have produced variable results. One reason for this discrepancy may be that prostaglandins are most important in early replication and differentiation of the osteoclast precursors. In organ culture and in vivo, there may already be ample numbers of osteoclast precursors available for the final stages of osteoclast precursor differentiation, fusion and activation. Hence, the cell culture models that was employed in the present study may be more representative of the hyperstimulation of osteoclastogenesis that occurs in pathologic conditions like inflammation, rather than physiologic bone remodeling.
Despite these reservations, the identification of the roles of EP 2 , and also of EP 4 receptors in mediating bone resorption should have important clinical implications. There is evidence that the bone loss associated with inflammation and immobilization is due to local production of prostaglandins (38, 39) . Moreover, in rodent models, prostaglandins that are produced in response to increased cytokines may mediate the increased bone resorption observed after ovariectomy (29) . Further studies in knockout animals and the develop- 
